Silence Therapeutics

Nasdaq: SLN · SEC EDGAR filings

Results on file1
Average 24h move+30.88%across 1 result with a complete 24h price
1 resultSilence Therapeutics
Met endpoint

Divesiran

Phase 2 Polycythemia Vera

Silence Therapeutics SLN

24h stock move +30.88%

For information only. Not investment or medical advice. Prices are historical, from consolidated market data, and may contain errors. Always check the original source.